FDA Inspection 1027425 — Frontida BioPharm LLC
The FDA completed an inspection of Frontida BioPharm LLC on July 20, 2017 in Philadelphia, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- July 20, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Philadelphia, PA (United States)